Articles | Volume 3, issue 1
https://doi.org/10.5194/mr-3-91-2022
https://doi.org/10.5194/mr-3-91-2022
Research article
 | 
20 May 2022
Research article |  | 20 May 2022

Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket

Stephan Grzesiek, Johannes Paladini, Judith Habazettl, and Rajesh Sonti

Viewed

Total article views: 2,374 (including HTML, PDF, and XML)
HTML PDF XML Total Supplement BibTeX EndNote
1,777 541 56 2,374 91 34 27
  • HTML: 1,777
  • PDF: 541
  • XML: 56
  • Total: 2,374
  • Supplement: 91
  • BibTeX: 34
  • EndNote: 27
Views and downloads (calculated since 28 Mar 2022)
Cumulative views and downloads (calculated since 28 Mar 2022)

Viewed (geographical distribution)

Total article views: 2,374 (including HTML, PDF, and XML) Thereof 2,107 with geography defined and 267 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 19 Apr 2024
Download
Short summary
We show here that binding of the anticancer drug imatinib to the ATP site of Abelson kinase and not binding to its allosteric site coincides with the opening of the kinase regulatory core at nanomolar concentrations. This has implications for the understanding of Abelson’s kinase regulation and activity during medication as well as for the design of new Abelson kinase inhibitors.